Eli Lilly Co Drug Patent Portfolio

Eli Lilly Co owns 1 orange book drug protected by 6 US patents Given below is the list of Eli Lilly Co's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6821975 Beta-carboline drug products 19 May, 2021 Expired
US6821975 Beta-carboline drug products 19 Nov, 2020 Expired
US7182958 β-carboline pharmaceutical compositions 26 Oct, 2020 Expired
US7182958 β-carboline pharmaceutical compositions 26 Apr, 2020 Expired
US5859006 Tetracyclic derivatives; process of preparation and use 21 May, 2018 Expired
US5859006 Tetracyclic derivatives; process of preparation and use 21 Nov, 2017 Expired


Given below is the list of recent legal activities going on the following drug patents of Eli Lilly Co.

Activity Date Patent Number
Patent litigations
Review Certificate Mailed 27 Jun, 2019 US6821975 (Litigated)
Review Certificate Mailed 26 Jun, 2019 US7182958 (Litigated)
Review Certificate 12 Jun, 2019 US7182958 (Litigated)
Review Certificate 12 Jun, 2019 US6821975 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 16 Jul, 2018 US7182958 (Litigated)
Termination or Final Written Decision 03 Aug, 2016 US6821975 (Litigated)
Termination or Final Written Decision 03 Aug, 2016 US7182958 (Litigated)
Request for Trial Granted 04 Aug, 2015 US7182958 (Litigated)
Petition Requesting Trial 13 Jan, 2015 US7182958 (Litigated)
Petition Requesting Trial 13 Jan, 2015 US6821975 (Litigated)
Post Issue Communication - Certificate of Correction 13 Nov, 2007 US7182958 (Litigated)
Patent Issue Date Used in PTA Calculation 27 Feb, 2007 US7182958 (Litigated)
Recordation of Patent Grant Mailed 27 Feb, 2007 US7182958 (Litigated)
Issue Notification Mailed 07 Feb, 2007 US7182958 (Litigated)
Dispatch to FDC 22 Jan, 2007 US7182958 (Litigated)


Eli Lilly Co's Drug Patent Litigations

Eli Lilly Co's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 13, 2015, against patent number US7182958. The petitioner Actelion Pharmaceuticals Ltd, challenged the validity of this patent, with ICOS Corporation as the respondent. Click below to track the latest information on how companies are challenging Eli Lilly Co's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6821975 January, 2015 FWD Entered
(03 Aug, 2016)
ICOS Corporation Actelion Pharmaceuticals Ltd
US7182958 January, 2015 FWD Entered
(03 Aug, 2016)
ICOS Corporation Actelion Pharmaceuticals Ltd


Eli Lilly Co's Family Patents


Family Patents



Eli Lilly Co Drug List

Given below is the complete list of Eli Lilly Co's drugs and the patents protecting them.


1. Adcirca

Adcirca is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6821975
(Pediatric)
Beta-carboline drug products 19 May, 2021
(3 years ago)
Expired
US6821975 Beta-carboline drug products 19 Nov, 2020
(3 years ago)
Expired
US7182958
(Pediatric)
β-carboline pharmaceutical compositions 26 Oct, 2020
(3 years ago)
Expired
US7182958 β-carboline pharmaceutical compositions 26 Apr, 2020
(4 years ago)
Expired
US5859006
(Pediatric)
Tetracyclic derivatives; process of preparation and use 21 May, 2018
(6 years ago)
Expired
US5859006 Tetracyclic derivatives; process of preparation and use 21 Nov, 2017
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adcirca's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Eli Lilly Co News

FDA to review decision to take Eli Lilly weight loss drug off shortage list - STAT News

12 Oct, 2024

FDA in the US will review its ruling that currently prohibits the production of customized versions of Lilly's weight loss medication

12 Oct, 2024

Novo Nordisk's $16.5B Acquisition of Catalent Faces Increased Scrutiny from FTC - BioSpace

11 Oct, 2024

Eli Lilly Sends Legal Notices to Compounders for Replicating Weight-Loss Medication

10 Oct, 2024

See More